The research showed that Sterilox Solution completely inactivated the H5N1 test strain and passed the US Environmental Protection Agency's recommended hard-surface disinfection test, which requires two-minutes contact time.

The study conducted by ATS Labs, an independent certified laboratory, tested the virucidal activity of the Sterilox Solution in decontaminating H5N1 avian influenza on hard surfaces. Previous PuriCore studies proved the effectiveness of Sterilox Solution against a common surrogate for the pandemic H5N1 avian influenza strain, the human influenza virus, A/Hong Kong 68 Strain.

This new H5N1 research builds upon PuriCore’s earlier microbiological research, including published studies last year showing the effectiveness of the Sterilox Solution against major outbreak pathogens such as norovirus, MRSA, and acinetobacter.

The Sterilox Solution mimics the natural anti-microbial hypochlorous acid produced by the human body to fight pathogens. A wide range of markets that depend upon controlling the spread of infectious pathogens—including food retail and foodservice, hospitality, medical device disinfection, and wound therapy—use Sterilox Systems.

“Pandemic avian influenza remains a concern for healthcare providers, governments, and the general population,” said Greg Bosch, CEO of PuriCore. “These study results further demonstrate that our safe and environmentally friendly Sterilox Solution is highly effective against H5N1 and other dangerous pathogens and can be used in a variety of settings including hotels, hospitals, schools, and cruise ships.”